search

Active clinical trials for "Immune System Diseases"

Results 281-290 of 37852

Triple Therapy in T1DM

Type 1 Diabetes Mellitus

To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy) improves glycemic control in patients with type 1 diabetes compared with semaglutide and insulin (dual therapy) and insulin only (standard) treatment.

Recruiting40 enrollment criteria

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

Castleman DiseaseCastleman's Disease1 more

The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.

Recruiting20 enrollment criteria

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Relapsed B Acute Lymphoblastic LeukaemiaRefractory B Acute Lymphoblastic Leukaemia

This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia

Recruiting20 enrollment criteria

Vitamin D3 For CGD Patients With BCGosis/Itis

Vitamin D3Chronic-granulomatous Disease1 more

When children with chronic granulomatous disease (CGD) got BCG infection the treatment would be a tough task. The goal of the proposed research is to observe weather vitamin D supplementation can help the CGD children get through this challenge.

Recruiting9 enrollment criteria

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL...

Follicular Lymphoma and Marginal Zone Lymphoma

This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

Recruiting22 enrollment criteria

Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

Diabetes MellitusType 1

The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a therapeutic option for T1D patients and potentially other autoimmune disorders.

Recruiting17 enrollment criteria

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With...

MyelomaMultiple

A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab. Patients will be randomized to either: Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy. Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy.

Recruiting63 enrollment criteria

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive...

Central Nervous System LymphomaSecondary Central Nervous System Lymphoma

Background: Secondary central nervous system lymphoma (sCNSL) is cancer that has spread to the central nervous system. Most drugs used to treat it do not cross the blood-brain barrier. This makes it hard to treat. Researchers hope that a new combination of drugs may be able to help. Objective: To find a better way to treat sCNSL. Eligibility: People ages 18 and older with sCNSL Design: Participants will be screened with: Medical history Physical exam Blood, urine, and heart tests Eye exam Tissue or tumor biopsy Collection of cerebrospinal fluid CT, PET, and MRI scans: Participants will like in a machine that takes pictures of the body. Bone marrow aspirations or biopsies: A needle will be inserted into the participant s hipbone. The needle will remove a small amount of marrow. Participants will take the study drugs in 21-day cycles. They will take some drugs by mouth. They will take others through a catheter: A small tube will be inserted into a vein in the arm, neck, or chest. They may have drugs given through a catheter placed through the brain or injected into the spinal canal. Participants will have regular visits during the study. These will include repeats of the screening test. They may also provide a saliva sample or have a cheek swab. Participants will have up to 4 treatment cycles. Participants will have a follow-up visit 30 days after their last treatment dose. Then they will have visits every 3-6 months for 3 years and then yearly....

Recruiting44 enrollment criteria

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL

MRD-positiveAcute Lymphoblastic Leukemia

To evaluate the safety and efficacy of CD19/CD22 Bispecific CAR-T for the treatment of MRD-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells.

Recruiting25 enrollment criteria

Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid

OsteoporosisBullous Pemphigoid

Bullous pemphigoid is the most common type of bullous skin disease and is clinically characterized by clear-tense bullae, which result in post-bullous cutaneous erosions, altering the skin barrier. The treatment of this pathology consists of the application of high doses of topical corticosteroids (clobetasol propionate) for a prolonged period of at least 6 months. The main objective of this study is to demonstrate a change in bone mineral density at 6 months after initiation of treatment, in subjects with bullous pemphigoid and treated with topical corticosteroid.

Recruiting8 enrollment criteria
1...282930...3786

Need Help? Contact our team!


We'll reach out to this number within 24 hrs